Breakthrough research shows that type 2 diabetes occurs when fat from the liver overspills into the pancreas and confirms that weight loss can reverse it.
Thoughts on this. True or BS.
DCA Dichloroacetate Breakthrough Anticancer Agent
Mary, an old patient in my office, called in last week to ask for advice about her husband, Jim. He had been quite healthy for many years, and recently noticed back pain. His primary care doctor ordered a CAT scan which showed a large lung mass (Red Arrow Above image) and destructive lesions in the spine. Biopsies confirmed the lung mass was indeed cancer, with metastatic spread to the thoracic vertebral bodies. Jim was referred to the local oncologist who started radiation and chemotherapy. Above Header Image CAT scan of lung cancer mass (Red Arrow) in left lung courtesy of wikimedia commons…
Continue reading “DCA Dichloroacetate Breakthrough Anticancer Agent” »
Physics has thrived over the last 10 years through some remarkable breakthroughs — and more excitement lies in store as a new decade dawns.
Professor Varda Shoshan-Barmatz of the Department of Life Sciences and the founding Director of the NIBN, in collaboration with Dr. Jay Chung of the NIH, have successfully demonstrated that the mitochondrial protein VDAC1 is critical for the release of mitochondrial DNA (mtDNA) associated with the lupus disease.
They demonstrated that restricting of VDAC1 with a newly developed molecule resulted in substantial improvement in pathological aspects of the disease.
“When VDAC1 is over-expressed, as found in several diseases, a large pore composed of several VDAC1 units is formed, allowing the release of pro-cell death factors and mtDNA,” BGU explained in a statement.
https://youtube.com/watch?v=BLJkX_RGpk0
Last November, CHIPSA Hospital hosted a unique, first-of-its-kind event celebrating the lives of 22 late stage cancer survivors who, according to doctors, shouldn’t even be alive. Surrounded by world-renowned doctors, scientists, and researchers, these patients shared their inspiring stories of how they healed their terminal disease when conventional treatment had failed them.
CHIPSA is not an ordinary hospital. For one, we take patients who are typically told they have no other treatment options left. We then offer those patients innovative immunotherapies that aren’t available anywhere in the United States.
Antibiotic-resistant bacteria are increasingly the source of deadly infections. A team of scientists from the Technical University of Munich (TUM) and the Helmholtz Center for Infection Research (HZI) in Braunschweig have now modified an approved cancer drug to develop an active agent against multidrug-resistant pathogens.
The methicillin-resistant Staphylococcus aureus (MRSA) is the source of severe and persistent infections. Some strains are even resistant to multiple antibiotics. There is consequently an urgent need for new drugs effective against MRSA infections.
“The industrial development of new antibiotics is stalling and not keeping pace with the spread of antibiotic resistance. We urgently need innovative approaches to meet the need for new infection therapies that do not lead directly to renewed resistance,” says Prof. Eva Medina, director of the HZI Infection Immunology Research Group.
Discover the latest features and innovations available in the 65 inches Class Q900 QLED Smart 8K UHD TV (2019). Find the perfect TVs for you!
Yoshua Bengio is known as one of the “three musketeers” of deep learning, the type of artificial intelligence (AI) that dominates the field today.
Bengio, a professor at the University of Montreal, is credited with making key breakthroughs in the use of neural networks — and just as importantly, with persevering with the work through the long cold AI winter of the late 1980s and the 1990s, when most people thought that neural networks were a dead end.
He was rewarded for his perseverance in 2018, when he and his fellow musketeers (Geoffrey Hinton and Yann LeCun) won the Turing Award, which is often called the Nobel Prize of computing.
Mount Sinai researchers have designed an innovative experimental therapy that may be able to stop the growth of triple-negative breast cancer, the deadliest type of breast cancer, which has few effective treatment options, according to a study published in Nature Chemical Biology in December.
The therapy is known is MS1943. In a cancer cell line and mouse models, it degraded a protein called EZH2 that drives the growth of triple-negative breast cancer.
Research teams led by Jian Jin, Ph.D., Director of the Mount Sinai Center for Therapeutics Discovery, and Ramon Parsons, MD, Ph.D., Director of The Tisch Cancer Institute at Mount Sinai, developed MS1943 as a first-in-class small-molecule agent that selectively degrades EZH2. They also showed that agents that inhibit the enzymatic activity of EZH2 but do not degrade EZH2 did not work in triple-negative breast cancer.
